MU
Michael Ulz Morgan Stanley Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
21
Avg Return
Past Year
Past Year
30%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
73.9%
Neutral
21.7%
Negative
4.3%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
---|---|---|---|---|---|---|---|---|
Overweight
Maintained
| $81 |
11%
upside
| 1 | -4.2% |
0
%
| 16 Oct ‘25 4 days ago |
|
|
Overweight
Maintained
| $90 |
22%
upside
| 3 | +20% |
0
%
| 16 Oct ‘25 4 days ago |
|
|
Outperform
Maintained
| $21 |
225%
upside
| 4 | +1.6% |
0
%
| 9 Oct ‘25 11 days ago |
|
|
Equal-Weight
Maintained
| $475 |
3%
downside
| 4 | – |
–
| 6 Oct ‘25 14 days ago |
|
|
Overweight
Maintained
| $25 |
248%
upside
| 2 | +40% |
0
%
| 9 May ‘25 5 months ago |
|
|
Overweight
Maintained
| $102 |
202%
upside
| 1 | +31% |
0
%
| 24 Apr ‘25 5 months ago |
|
|
Overweight
Maintained
| $20 |
167%
upside
| 1 | +289% |
0
%
| 1 Apr ‘25 6 months ago |
|
|
Overweight
Maintained
| $22 |
680%
upside
| 1 | +102% |
0
%
| 1 Apr ‘25 6 months ago |
|
|
Overweight
Initiated
| $29 |
136%
upside
| 1 | +21% |
0
%
| 10 Mar ‘25 7 months ago |
|
|
Underweight
Maintained
| $7 | – | 1 | -73% |
0
%
| 5 Mar ‘25 7 months ago |
|
|
Outperform
Maintained
| $20 |
762%
upside
| 1 | -56% |
0
%
| 28 Feb ‘25 7 months ago |
|
|
Equal-Weight
Downgraded
| $5 |
7%
downside
| 1 | – |
–
| 12 Feb ‘25 8 months ago |
|
|
Overweight
Maintained
| $10 |
619%
upside
| 1 | -23% |
0
%
| 3 Feb ‘25 8 months ago |
|
|
Overweight
Maintained
| $96 |
78%
upside
| 1 | +4.3% |
0
%
| 28 Jan ‘25 8 months ago |
|